Aliases & Classifications for Common Wart

MalaCards integrated aliases for Common Wart:

Name: Common Wart 12 15 17 74


External Ids:

Disease Ontology 12 DOID:11165
ICD9CM 36 078.1
NCIt 51 C27087 C5028
ICD10 34 B07 B07.8
UMLS 74 C0043037

Summaries for Common Wart

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in human papillomavirus (types 2 and 4). This infection has symptom raised wart with roughened surface, most common on hands, but can grow anywhere on the body.

MalaCards based summary : Common Wart is related to measles and mycobacterium abscessus, and has symptoms including raised wart An important gene associated with Common Wart is CLEC7A (C-Type Lectin Domain Containing 7A), and among its related pathways/superpathways are Innate Immune System and Activated TLR4 signalling. The drugs Miconazole and Salicylic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, skin and kidney, and related phenotypes are hematopoietic system and immune system

Related Diseases for Common Wart

Diseases related to Common Wart via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 47)
# Related Disease Score Top Affiliating Genes
1 measles 30.1 CD209 TLR2 TLR3
2 mycobacterium abscessus 10.1 CLEC7A TLR1 TLR2
3 neurosyphilis 10.1 TLR1 TLR2 TLR6
4 superficial basal cell carcinoma 10.1 TLR7 TLR8 TLR9
5 ocular toxoplasmosis 10.1 TLR1 TLR5 TLR9
6 legionnaires' disease 10.1 TLR5 TLR6 TLR9
7 pelvic inflammatory disease 10.1 TLR1 TLR2 TLR6
8 q fever 10.1 TLR1 TLR10 TLR2
9 lyme disease 10.1 TLR1 TLR2 TLR6
10 mucocutaneous leishmaniasis 10.0 TLR3 TLR9
11 mumps 10.0
12 rubella 10.0
13 haemophilus influenzae 10.0 CLEC7A TLR2
14 juvenile nasopharyngeal angiofibroma 10.0 TLR3 TLR7 TLR9
15 suppurative otitis media 10.0 TLR2 TLR5 TLR9
16 septic arthritis 10.0 TLR2 TLR5 TLR9
17 aspergillosis 10.0 CD209 CLEC7A TLR2 TLR9
18 toxoplasmosis 10.0 CD40 TLR2 TLR9
19 urethritis 10.0 TLR1 TLR6
20 myd88 deficiency 10.0 TLR1 TLR2 TLR5 TLR6
21 melioidosis 10.0 TLR1 TLR10 TLR2 TLR5
22 sulfamethoxazole allergy 10.0 CD40 CD80
23 oral cavity cancer 10.0 TLR2 TLR6 TLR9
24 penicilliosis 10.0 CD40 TLR1 TLR2 TLR6
25 filariasis 9.9 TLR1 TLR2 TLR6 TLR9
26 mycobacterium tuberculosis 1 9.9 CD209 TLR1 TLR2 TLR9
27 pneumonia 9.9 TLR2 TLR5 TLR9
28 spondylarthropathy 9.9 CD40 CD80 TLR2
29 myositis fibrosa 9.9 CD80 TLR2 TLR9
30 irak4 deficiency 9.9 TLR1 TLR10 TLR2 TLR5 TLR6
31 fungal keratitis 9.9 CD209 CLEC4E CLEC7A TLR2
32 invasive aspergillosis 9.8 CLEC7A TLR1 TLR2 TLR6 TLR9
33 viral infectious disease 9.8 CD209 TLR3 TLR7 TLR8 TLR9
34 cutis laxa, autosomal dominant 1 9.8 CD80 TLR2 TLR9
35 epidermodysplasia verruciformis 1 9.8
36 lymphedema 9.8
37 squamous cell carcinoma 9.8
38 melanoma 9.8
39 verrucous carcinoma 9.8
40 conjunctivitis 9.8
41 in situ carcinoma 9.8
42 molluscum contagiosum 9.8
43 bowen's disease 9.8
44 opportunistic mycosis 9.8 CLEC6A CLEC7A TLR2 TLR9
45 bacterial infectious disease 9.7 TLR1 TLR2 TLR3 TLR5 TLR9
46 immune system disease 9.7 TLR1 TLR10 TLR3 TLR5 TLR6 TLR9
47 systemic lupus erythematosus 9.3 CD40 CD80 TLR2 TLR5 TLR7 TLR9

Graphical network of the top 20 diseases related to Common Wart:

Diseases related to Common Wart

Symptoms & Phenotypes for Common Wart


  • raised wart

MGI Mouse Phenotypes related to Common Wart:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CD40 CD80 CLEC4E CLEC6A CLEC7A LGALS3
2 immune system MP:0005387 9.8 CD40 CD80 CLEC4E CLEC6A CLEC7A LGALS3
3 renal/urinary system MP:0005367 9.17 CD40 CLEC6A LGALS3 TLR2 TLR7 TLR8

Drugs & Therapeutics for Common Wart

Drugs for Common Wart (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 22916-47-8 4189
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 69-72-7 338
Cantharidin Approved, Investigational Phase 4,Phase 2,Not Applicable 56-25-7
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7440-66-6 32051
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
Fluorouracil Approved Phase 4 51-21-8 3385
Epicatechin Investigational Phase 4,Phase 1 490-46-0, 35323-91-2 72276
9 Salicylates Phase 4,Phase 2,Phase 3
10 Dermatologic Agents Phase 4,Phase 2,Phase 3,Not Applicable
11 Analgesics Phase 4,Phase 2,Phase 3
12 pyruvate Phase 4,Phase 2,Phase 3
13 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
15 Keratolytic Agents Phase 4,Phase 2,Phase 3,Not Applicable
16 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
17 Antirheumatic Agents Phase 4,Phase 2,Phase 3
18 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3
19 Antifungal Agents Phase 4,Phase 2,Phase 3
20 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
21 Cyclooxygenase Inhibitors Phase 4,Phase 2,Phase 3
22 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Liver Extracts Phase 4,Phase 3
25 Antibodies Phase 4,Phase 3,Phase 1
26 Immunoglobulins Phase 4,Phase 3,Phase 1
27 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Tea Phase 4,Phase 3,Phase 2,Phase 1
33 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1
34 Cyclosporins Phase 4
35 Calcineurin Inhibitors Phase 4
36 Anti-Bacterial Agents Phase 4,Phase 2
37 Nutrients Phase 4,Phase 2,Phase 3,Not Applicable
38 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
39 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
40 Antimetabolites, Antineoplastic Phase 4,Phase 1,Phase 2
41 Antimetabolites Phase 4,Phase 1,Phase 2
42 insulin Phase 4,Phase 3
43 Insulin, Globin Zinc Phase 4,Phase 3
44 Antibiotics, Antitubercular Phase 4
Ethanol Approved Phase 2, Phase 3,Phase 3,Not Applicable 64-17-5 702
Petrolatum Approved, Investigational Phase 2, Phase 3,Phase 3 8009-03-8
Aminolevulinic acid Approved Phase 3,Not Applicable 106-60-5 137
Furosemide Approved, Vet_approved Phase 3,Phase 2 54-31-9 3440
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Pancrelipase Approved, Investigational Phase 3 53608-75-6

Interventional clinical trials:

(show top 50) (show all 214)
# Name Status NCT ID Phase Drugs
1 17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts Unknown status NCT01712295 Phase 4 17% Salicylate with ethyl pyruvate;Salicylates
2 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
3 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
4 Cantharone for the Treatment of Perenial Warts Completed NCT03625960 Phase 4 Cantharidin;Trichloroacetic Acid
5 Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients Completed NCT00761371 Phase 4 Imiquimod 5% cream
6 Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts Completed NCT00189293 Phase 4 Imiquimod
7 Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study Completed NCT02622568 Phase 4 Veregen only
8 Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage Completed NCT01082302 Phase 4 Polyphenon E (Veregen) 15% ointment
9 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
10 Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A Completed NCT02547714 Phase 4 Secukinumab (AIN457)
11 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Completed NCT02087384 Phase 4 Placebo
12 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
13 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
14 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
15 A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts Terminated NCT01468636 Phase 4 Oral Zinc;Placebo
16 Comparison of Five Treatments in Patients With Plantar Warts Terminated NCT01059110 Phase 4 Salicylate ointment;Imiquimod;5-Fluoro-Uracil;Cryotherapy
17 Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients Unknown status NCT03153566 Phase 3
18 Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Unknown status NCT02151630 Phase 2, Phase 3 Pyruvic acid;Salicylic Acid
19 Efficacy of Laser Versus Cryotherapy in the Treatment of Warts Unknown status NCT01808443 Phase 3
20 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
21 A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts Completed NCT03259620 Phase 3 CLS006;CLS006 Vehicle
22 A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts Completed NCT02971891 Phase 3 CLS006 (Furosemide) Topical Gel;Vehicle Topical Gel
23 Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3 2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream
24 Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00674739 Phase 3 Imiquimod;3.75% imiquimod cream;placebo cream
25 Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial Completed NCT01783353 Phase 2, Phase 3
26 Low Dose Cyclophosphamide Treats Genital Warts Completed NCT00999986 Phase 3 cyclophosphamide
27 Glizigen-Viudid-External Anogenital Warts in Children and Adolescents Completed NCT01111344 Phase 3
28 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
29 Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts Completed NCT00449982 Phase 3 Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
30 An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) Completed NCT00090285 Phase 3
31 PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
32 Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED) Completed NCT00517309 Phase 3
33 A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine Completed NCT00501137 Phase 3
34 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015) Completed NCT00092534 Phase 3
35 Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) Completed NCT00092495 Phase 3
36 Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) Completed NCT00092482 Phase 3
37 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed NCT01047345 Phase 3
38 Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients Completed NCT00677677 Phase 3
39 Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) Completed NCT01651949 Phase 3
40 Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
41 Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Completed NCT00423046 Phase 3
42 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
43 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Completed NCT03158220 Phase 3
44 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
45 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
46 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
47 GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Completed NCT01245764 Phase 3
48 Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis Completed NCT01412944 Phase 3 secukinumab 150mg;secukinumab 10mg/kg i.v. regimen
49 Study of A-101 Topical Solution for the Treatment of Common Warts Recruiting NCT03687372 Phase 3 A-101
50 Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts Recruiting NCT03158168 Phase 3 Candida Antigen;Zinc Sulfate

Search NIH Clinical Center for Common Wart

Genetic Tests for Common Wart

Anatomical Context for Common Wart

The Foundational Model of Anatomy Ontology organs/tissues related to Common Wart:


MalaCards organs/tissues related to Common Wart:

Skin, Kidney, Liver, Testes, Bone, T Cells

Publications for Common Wart

Articles related to Common Wart:

(show all 21)
# Title Authors Year
Hyperkeratotic acral melanoma mimicking a common wart. ( 25973355 )
Keratotic horn on left fifth fingertip: congenital ectopic nail misdiagnosed as a common wart. ( 22277059 )
Comparative study of topical 80% trichloroacetic acid with 35% trichloroacetic acid in the treatment of the common wart. ( 23135096 )
Treatment options for the common wart. ( 18210913 )
Plantar verrucous carcinoma (epithelloma cuniculatum): rare form of the common wart. ( 17214114 )
Is duct tape occlusion therapy as effective as cryotherapy for the treatment of the common wart? ( 12361441 )
The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart). ( 12361440 )
Human papillomavirus associated Bowen's disease of the foot: unique clinical features mimicking a common wart. ( 11525958 )
Efficacious treatment of the common wart (verruca vulgaris). ( 1462533 )
Common wart causing longitudinal groove in nail. ( 28150682 )
Stump the experts. A common wart. ( 7338585 )
Transformation of the common wart into squamous cell carcinoma in a patient with primary lymphedema. ( 7248909 )
An unusual transformation of a common wart in a child. ( 6269499 )
Treatment of the common wart by induced allergic inflammation. ( 7389963 )
The common wart: intralesional treatment with bleomycin sulfate. ( 6159138 )
Treatment of the common wart with a virus vaccine. ( 14477428 )
Morphological characterization of the virus of the human common wart (verruca vulgaris). ( 13785470 )
Aralen and plaquenil in treatment of the common wart. ( 13726985 )
Common wart conjunctivitis. ( 13196997 )
Treatment of the common wart by x-ray therapy. ( 13164671 )
Contact x-ray therapy of the common wart. ( 14914174 )

Variations for Common Wart

Expression for Common Wart

Search GEO for disease gene expression data for Common Wart.

Pathways for Common Wart

Pathways related to Common Wart according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
Show member pathways
14.02 CD209 CD40 CD80 CLEC4E CLEC6A CLEC7A
Show member pathways
13.52 TLR1 TLR10 TLR2 TLR3 TLR5 TLR6
Show member pathways
13.43 CD40 CD80 TLR1 TLR10 TLR2 TLR3
Show member pathways
13.25 CD40 TLR1 TLR10 TLR2 TLR3 TLR5
Show member pathways
13.08 CD40 CD80 IFNA8 TLR1 TLR10 TLR2
Show member pathways
12.72 CD40 TLR1 TLR10 TLR2 TLR3 TLR5
Show member pathways
12.66 CD40 TLR1 TLR10 TLR2 TLR3 TLR5
Show member pathways
12.48 TLR1 TLR10 TLR2 TLR3 TLR5 TLR6
10 12.33 CD209 CLEC4E CLEC7A IFNA8 TLR1 TLR2
Show member pathways
Show member pathways
12.29 TLR1 TLR10 TLR2 TLR3 TLR5 TLR6
Show member pathways
Show member pathways
Show member pathways
12.25 TLR1 TLR10 TLR2 TLR3 TLR5 TLR6
16 12.13 TLR1 TLR10 TLR2 TLR3 TLR5 TLR6
17 12.07 CD209 CLEC7A TLR2 TLR6
Show member pathways
11.98 CD40 TLR1 TLR2 TLR6
Show member pathways
20 11.65 CD209 TLR7 TLR9
21 11.58 CLEC7A TLR1 TLR10 TLR2 TLR3 TLR5
22 11.46 CD40 TLR2 TLR9
Show member pathways
11.44 CD80 TLR1 TLR10 TLR2 TLR3 TLR5

GO Terms for Common Wart

Cellular components related to Common Wart according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.88 TLR1 TLR2 TLR6 TLR7 TLR9
2 cell surface GO:0009986 9.85 CD209 CD40 CD80 LGALS3 TLR2 TLR3
3 plasma membrane GO:0005886 9.83 CD209 CD40 CD80 CLEC4E CLEC6A CLEC7A
4 external side of plasma membrane GO:0009897 9.8 CD209 CD40 CD80 TLR8
5 endosome membrane GO:0010008 9.76 TLR3 TLR7 TLR8 TLR9
6 phagocytic vesicle membrane GO:0030670 9.61 TLR1 TLR2 TLR6
7 early phagosome GO:0032009 9.4 TLR7 TLR9
8 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 9.26 TLR1 TLR2
9 endolysosome membrane GO:0036020 8.92 TLR3 TLR7 TLR8 TLR9
10 membrane GO:0016020 10.22 CD209 CD40 CD80 CLEC4E CLEC6A CLEC7A
11 integral component of membrane GO:0016021 10.03 CD209 CD40 CD80 CLEC4E CLEC6A CLEC7A

Biological processes related to Common Wart according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 cellular response to mechanical stimulus GO:0071260 9.98 CD40 TLR3 TLR5 TLR7 TLR8
2 positive regulation of inflammatory response GO:0050729 9.97 TLR10 TLR2 TLR3 TLR7 TLR9
3 positive regulation of interleukin-6 production GO:0032755 9.95 TLR2 TLR3 TLR7 TLR8 TLR9
4 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.93 TLR3 TLR7 TLR8 TLR9
5 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.92 TLR2 TLR3 TLR7 TLR9
6 positive regulation of interleukin-8 production GO:0032757 9.88 TLR2 TLR3 TLR5 TLR7 TLR9
7 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.87 CD209 CLEC4E CLEC6A
8 positive regulation of interleukin-12 production GO:0032735 9.87 CD40 TLR2 TLR3 TLR9
9 positive regulation of tumor necrosis factor production GO:0032760 9.86 TLR2 TLR3 TLR9
10 positive regulation of chemokine production GO:0032722 9.86 TLR2 TLR3 TLR7 TLR9
11 microglial cell activation GO:0001774 9.85 TLR2 TLR3 TLR6 TLR7 TLR8
12 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.84 TLR3 TLR7 TLR8 TLR9
13 positive regulation of interferon-beta production GO:0032728 9.83 TLR2 TLR3 TLR9
14 I-kappaB phosphorylation GO:0007252 9.83 TLR2 TLR3 TLR7 TLR9
15 toll-like receptor 9 signaling pathway GO:0034162 9.81 TLR7 TLR8 TLR9
16 positive regulation of interferon-beta biosynthetic process GO:0045359 9.81 TLR3 TLR7 TLR8 TLR9
17 cell activation GO:0001775 9.8 TLR1 TLR2 TLR6
18 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.78 TLR7 TLR8 TLR9
19 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.76 TLR1 TLR10 TLR2 TLR5 TLR6 TLR7
20 positive regulation of interferon-alpha biosynthetic process GO:0045356 9.73 TLR3 TLR7 TLR8 TLR9
21 defense response to protozoan GO:0042832 9.71 CD40 CLEC7A
22 positive regulation of toll-like receptor signaling pathway GO:0034123 9.71 TLR2 TLR3 TLR5 TLR9
23 activation of NF-kappaB-inducing kinase activity GO:0007250 9.7 TLR3 TLR6
24 positive regulation of interleukin-8 secretion GO:2000484 9.7 TLR1 TLR2
25 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.7 TLR2 TLR9
26 response to molecule of bacterial origin GO:0002237 9.7 TLR2 TLR9
27 regulation of T cell proliferation GO:0042129 9.69 CD209 LGALS3
28 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.69 TLR1 TLR6
29 positive regulation of interleukin-18 production GO:0032741 9.68 TLR2 TLR9
30 tumor necrosis factor production GO:0032640 9.68 TLR2 TLR9
31 cellular response to diacyl bacterial lipopeptide GO:0071726 9.68 TLR2 TLR6
32 toll-like receptor TLR6:TLR2 signaling pathway GO:0038124 9.67 TLR2 TLR6
33 cellular response to triacyl bacterial lipopeptide GO:0071727 9.67 TLR1 TLR2
34 nitric oxide metabolic process GO:0046209 9.67 TLR2 TLR6
35 toll-like receptor TLR1:TLR2 signaling pathway GO:0038123 9.66 TLR1 TLR2
36 detection of diacyl bacterial lipopeptide GO:0042496 9.65 TLR2 TLR6
37 detection of triacyl bacterial lipopeptide GO:0042495 9.65 TLR1 TLR2
38 response to bacterial lipoprotein GO:0032493 9.65 TLR2 TLR6
39 toll-like receptor signaling pathway GO:0002224 9.56 TLR1 TLR10 TLR2 TLR3 TLR6 TLR7
40 regulation of cytokine secretion GO:0050707 9.17 TLR1 TLR10 TLR2 TLR5 TLR6 TLR8
41 signal transduction GO:0007165 10.34 CD80 NR2E3 TLR1 TLR10 TLR2 TLR3
42 immune system process GO:0002376 10.2 CD209 CD40 CLEC4E CLEC6A CLEC7A LGALS3
43 positive regulation of transcription by RNA polymerase II GO:0045944 10.18 CD40 NFIC NR2E3 TLR2 TLR3 TLR9
44 immune response GO:0006955 10.15 CD80 CLEC4E TLR1 TLR10 TLR2 TLR6
45 inflammatory response GO:0006954 10.11 CD40 CLEC7A TLR1 TLR10 TLR2 TLR3
46 innate immune response GO:0045087 10.1 CD209 CLEC4E CLEC6A CLEC7A LGALS3 TLR1
47 defense response to virus GO:0051607 10.07 CD40 IFNA8 TLR3 TLR7 TLR8 TLR9
48 defense response to bacterium GO:0042742 10.04 CLEC4E TLR3 TLR5 TLR6 TLR9
49 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.03 CD40 CLEC6A TLR3 TLR6 TLR9
50 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.01 CD40 TLR2 TLR3 TLR6 TLR9

Molecular functions related to Common Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.72 CD209 CLEC4E CLEC6A CLEC7A LGALS3
2 signaling receptor activity GO:0038023 9.7 CD40 CLEC4E TLR1 TLR2 TLR3 TLR6
3 double-stranded RNA binding GO:0003725 9.58 TLR3 TLR7 TLR8
4 transmembrane signaling receptor activity GO:0004888 9.56 TLR1 TLR10 TLR3 TLR5 TLR6 TLR7
5 mannose binding GO:0005537 9.48 CD209 CLEC6A
6 interleukin-1 receptor binding GO:0005149 9.46 TLR5 TLR9
7 siRNA binding GO:0035197 9.43 TLR7 TLR9
8 lipopeptide binding GO:0071723 9.43 TLR1 TLR2 TLR6
9 Toll-like receptor 2 binding GO:0035663 9.37 TLR1 TLR6
10 signaling pattern recognition receptor activity GO:0008329 9.02 CLEC7A TLR2 TLR7 TLR8 TLR9

Sources for Common Wart

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
33 HPO
34 ICD10
35 ICD10 via Orphanet
39 LifeMap
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
56 Novoseek
59 OMIM via Orphanet
63 PubMed
71 SNOMED-CT via Orphanet
73 Tocris
75 UMLS via Orphanet
Loading form....